India · Delayed Price · Currency is INR Orchid Pharma Statistics
Total Valuation
Orchid Pharma has a market cap or net worth of INR 39.17 billion. The enterprise value is 39.11 billion.
| Market Cap | 39.17B |
| Enterprise Value | 39.11B |
Important Dates
The last earnings date was Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 50.72M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.95% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 15.19M |
Valuation Ratios
The trailing PE ratio is 45.96 and the forward PE ratio is 34.37.
| PE Ratio | 45.96 |
| Forward PE | 34.37 |
| PS Ratio | 4.61 |
| PB Ratio | 3.09 |
| P/TBV Ratio | 3.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 45.90 |
| EV / Sales | 4.60 |
| EV / EBITDA | 37.84 |
| EV / EBIT | 57.42 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 1.76 |
| Debt / FCF | n/a |
| Interest Coverage | 4.48 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 2.92% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 9.76M |
| Profits Per Employee | 978,379 |
| Employee Count | 871 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -394,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.54% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -44.54% |
| 50-Day Moving Average | 732.76 |
| 200-Day Moving Average | 1,070.10 |
| Relative Strength Index (RSI) | 56.05 |
| Average Volume (20 Days) | 6,829 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orchid Pharma had revenue of INR 8.50 billion and earned 852.17 million in profits. Earnings per share was 16.80.
| Revenue | 8.50B |
| Gross Profit | 3.58B |
| Operating Income | 641.03M |
| Pretax Income | 851.77M |
| Net Income | 852.17M |
| EBITDA | 993.43M |
| EBIT | 641.03M |
| Earnings Per Share (EPS) | 16.80 |
Balance Sheet
The company has 1.80 billion in cash and 1.75 billion in debt, giving a net cash position of 51.25 million.
| Cash & Cash Equivalents | 1.80B |
| Total Debt | 1.75B |
| Net Cash | 51.25M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 12.67B |
| Book Value Per Share | 250.11 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 42.05%, with operating and profit margins of 7.54% and 10.02%.
| Gross Margin | 42.05% |
| Operating Margin | 7.54% |
| Pretax Margin | 10.02% |
| Profit Margin | 10.02% |
| EBITDA Margin | 11.68% |
| EBIT Margin | 7.54% |
| FCF Margin | n/a |
Dividends & Yields
Orchid Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.95% |
| Shareholder Yield | n/a |
| Earnings Yield | 2.18% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |